Liver Transplantation for Hepatocellular Carcinoma in Young Adults: A United Network for Organ Sharing Study

被引:3
作者
Thomas, Stefanie M. [1 ,2 ]
Moke, Diana [1 ]
Lopez, Rocio [3 ]
Hanna, Rabi [4 ]
Kabbany, Mohammad Nasser [5 ]
Alkhouri, Naim [5 ,6 ]
机构
[1] Childrens Hosp Los Angeles, Childrens Ctr Canc & Blood Dis, Los Angeles, CA 90027 USA
[2] Univ Southern Calif, Keck Sch Med, Dept Pediat, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA 90033 USA
[3] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA
[4] Cleveland Clin Childrens, Dept Pediat Hematol Oncol & Blood & Marrow Transp, Cleveland, OH USA
[5] Cleveland Clin, Dept Pediat Gastroenterol & Hepatol, Cleveland, OH 44106 USA
[6] Cleveland Clin, Digest Dis Inst, Cleveland, OH 44106 USA
关键词
hepatitis B virus; model for end-stage liver disease; surgical oncology; CLINICAL CHARACTERISTICS; SURVIVAL; PROGNOSIS; MORTALITY; FEATURES; COHORT; IMPACT;
D O I
10.1089/jayao.2016.0048
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Orthotopic liver transplantation (OLT) is curative for hepatocellular carcinoma (HCC). HCC is typically a disease of older adults (OAs); therefore, characteristics and outcomes of OLT for young adults (YAs) (ages 18-40) are not described. The objective of this study was to assess the characteristics and outcomes of YAs with HCC receiving OLT and compare these to OAs (ages >40 years). Methods: YAs with HCC who had OLT from the United Network for Organ Sharing (UNOS) database were included in this study. As a comparison group, OAs with HCC were matched 4:1 to the YA group. Descriptive statistics of demographics, comorbidities, and outcomes were generated. Kaplan-Meier product limit estimates were used to assess patient and graft survival. Conditional logistic regression and Cox proportional hazards frailty models were used to compare the groups. Results: A total of 464 YAs received OLT for HCC. The most common underlying liver diseases were hepatitis C virus (21.3%), hepatitis B virus (HBV, 15.5%), and autoimmune/cholestatic disease (12.3%). An increased number of YAs received OLT for HCC after implementation of model for end-stage liver disease scoring. One thousand two hundred eighty OAs served as the comparison group. Post-transplant 5-year survival was 73.1% in YAs with a retransplantation rate of 7.8%. In OAs, survival and retransplantation rates were lower (68.6% p=0.093; 4.3% p=0.001). Conclusion: Four hundred sixty-four YAs with HCC received OLT in the UNOS database. Compared to the older population, survival and retransplantation rates were higher. HBV, which is vaccine preventable, is a frequent contributor to HCC in YAs.
引用
收藏
页码:286 / 293
页数:8
相关论文
共 24 条
[1]   Liver transplantation for nonalcoholic steatohepatitis in young patients [J].
Alkhouri, Naim ;
Hanouneh, Ibrahim A. ;
Zein, Nizar N. ;
Lopez, Rocio ;
Kelly, Dympna ;
Eghtesad, Bijan ;
Fung, John J. .
TRANSPLANT INTERNATIONAL, 2016, 29 (04) :418-424
[2]   Changing Hepatocellular Carcinoma Incidence and Liver Cancer Mortality Rates in the United States [J].
Altekruse, Sean F. ;
Henley, S. Jane ;
Cucinelli, James E. ;
McGlynn, Katherine A. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (04) :542-553
[3]   Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005 [J].
Altekruse, Sean F. ;
McGlynn, Katherine A. ;
Reichman, Marsha E. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1485-1491
[4]   The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis [J].
Ascha, Mustafa S. ;
Hanouneh, Ibrahim A. ;
Lopez, Rocio ;
Tamimi, Tarek Abu-Rajab ;
Feldstein, Ariel F. ;
Zein, Nizar N. .
HEPATOLOGY, 2010, 51 (06) :1972-1978
[5]   Optimal matching with a variable number of controls vs. a fixed number of controls for a cohort study: trade-offs [J].
Cepeda, MS ;
Boston, R ;
Farrar, JT ;
Strom, BL .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (03) :230-237
[6]   Is the prognosis of young patients with hepatocellular carcinoma poorer than the prognosis of older patients? A comparative analysis of clinical characteristics, prognostic features, and survival outcome [J].
Chang, Pik-Eu ;
Ong, Wai-Choung ;
Lui, Hock-Foong ;
Tan, Chee-Kiat .
JOURNAL OF GASTROENTEROLOGY, 2008, 43 (11) :881-888
[7]   Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Dikshit, Rajesh ;
Eser, Sultan ;
Mathers, Colin ;
Rebelo, Marise ;
Parkin, Donald Maxwell ;
Forman, David ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386
[8]   Management of hepatocellular carcinoma [J].
Fitzmorris, P. ;
Shoreibah, M. ;
Anand, B. S. ;
Singal, A. K. .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (05) :861-876
[9]   Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: Where do we stand? [J].
Fujiki, Masato ;
Aucejo, Federico ;
Choi, Minsig ;
Kim, Richard .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (18) :5308-5319
[10]  
Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21254, 10.3322/caac.21332, 10.3322/caac.21551, 10.3322/caac.20073, 10.3322/caac.21387, 10.3322/caac.21654, 10.3322/caac.21601]